SIGA Key Statistics, Chart & Performance
The current stock price of SIGA is 6.27 USD. In the past month the price increased by 0.48%. In the past year, price decreased by -0.95%.
SIGA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 49.13 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 19.98 | 499.57B | ||
| MRK | MERCK & CO. INC. | 12.08 | 264.21B | ||
| PFE | PFIZER INC | 7.87 | 143.17B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.15 | 108.83B | ||
| ZTS | ZOETIS INC | 19.86 | 55.49B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.45 | 22.43B | ||
| VTRS | VIATRIS INC | 5.35 | 14.35B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.46 | 11.19B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.01B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.56B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.43B |
Related stock screener links
About SIGA
Company Profile
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for medical needs and biothreats. The company is headquartered in New York City, New York and currently employs 46 full-time employees. The firm is focused on the development of medicines to treat and prevent infectious diseases. Its flagship product, TPOXX (tecovirimat), is an antiviral medicine approved in the United States and Canada for the treatment of smallpox and authorized in Europe, the United Kingdom, and Japan for the treatment of smallpox, monkeypox (mpox), cowpox, and vaccinia complications. TPOXX specifically inhibits the activity of a protein called VP37, found on the surface of all orthopoxviruses. This prevents the virus from leaving infected cells, slowing the spread of the infection and limiting it to a point where the immune system can clear the virus. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox.
Company Info
SIGA TECHNOLOGIES INC
31 East 62Nd Street
New York City NEW YORK 10065 US
CEO: Phillip L. Gomez
Employees: 46
Phone: 12126729100
SIGA TECHNOLOGIES INC / SIGA FAQ
Can you describe the business of SIGA TECHNOLOGIES INC?
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for medical needs and biothreats. The company is headquartered in New York City, New York and currently employs 46 full-time employees. The firm is focused on the development of medicines to treat and prevent infectious diseases. Its flagship product, TPOXX (tecovirimat), is an antiviral medicine approved in the United States and Canada for the treatment of smallpox and authorized in Europe, the United Kingdom, and Japan for the treatment of smallpox, monkeypox (mpox), cowpox, and vaccinia complications. TPOXX specifically inhibits the activity of a protein called VP37, found on the surface of all orthopoxviruses. This prevents the virus from leaving infected cells, slowing the spread of the infection and limiting it to a point where the immune system can clear the virus. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox.
Can you provide the latest stock price for SIGA TECHNOLOGIES INC?
The current stock price of SIGA is 6.27 USD. The price increased by 2.62% in the last trading session.
Does SIGA TECHNOLOGIES INC pay dividends?
SIGA TECHNOLOGIES INC (SIGA) has a dividend yield of 9.57%. The yearly dividend amount is currently 0.6.
How is the ChartMill rating for SIGA TECHNOLOGIES INC?
SIGA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 8 out of 10.
What is the GICS sector and industry of SIGA stock?
SIGA TECHNOLOGIES INC (SIGA) operates in the Health Care sector and the Pharmaceuticals industry.
How many employees does SIGA TECHNOLOGIES INC have?
SIGA TECHNOLOGIES INC (SIGA) currently has 46 employees.
Can you provide the market cap for SIGA TECHNOLOGIES INC?
SIGA TECHNOLOGIES INC (SIGA) has a market capitalization of 448.99M USD. This makes SIGA a Small Cap stock.
SIGA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to SIGA. When comparing the yearly performance of all stocks, SIGA is a bad performer in the overall market: 80.3% of all stocks are doing better.
SIGA Fundamental Analysis
ChartMill assigns a fundamental rating of 8 / 10 to SIGA. SIGA gets an excellent profitability rating and is at the same time showing great financial health properties.
SIGA Financial Highlights
Over the last trailing twelve months SIGA reported a non-GAAP Earnings per Share(EPS) of 1.02. The EPS decreased by -15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 43.37% | ||
| ROA | 32.26% | ||
| ROE | 36.72% | ||
| Debt/Equity | 0 |
SIGA Forecast & Estimates
For the next year, analysts expect an EPS growth of -52.73% and a revenue growth -39.14% for SIGA